Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVM-V001 and RVM-V002 Booster Study in Healthy Adults
NCT05788185Phase 2Terminated
- Sponsor
- RVAC Medicines
- Start
- Mar 2023
- Primary completion
- Sep 2023
- Modality
- Vaccine mRNA, mRNA Vaccines, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of RVM-V001 and RVM-V002 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by RVAC Medicines. Primary endpoints: Safety in terms of solicited adverse events, Safety in terms of unsolicited adverse events and 1 more. Started Mar 2023; status: terminated.
02
Drugs
RVM-V001RVM-V002
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05788185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788185.